Who Drove the ESMO 2026 Conversation, and Who Amplified It
1,199 physicians discussed ESMO 2026 on X. Top KOLs, amplifiers, trials and US states for lung, breast, GU and GI cancer, with 8 public network maps.
“New Standard of Care”? Lung Cancer KOLs on KRASCENDO-1 and ESMO26
ESMO26 lung KOL reactions: KRASCENDO-1 OS HR 0.56, PERSEE PFS HR 0.56, DeLLphi-305 OS HR 0.42, and four China-only ADC trials in NSCLC.
ESMO 2026: Oncology is the Tip of the Spear for AI in Healthcare
ESMO 2026: oncology leads OpenEvidence use (JAMA), and digital opinion leaders moved INTerpath-001, NADINA and KRASCENDO-1 debates at X speed.
ESMO 2026 Day 3: Top Trials and KOL Reactions
ESMO 2026 Day 3: KRASCENDO-1 and the crossover question, SAFFRON, HARMONi-GI1, CLARITY-Gastric01, PERSEE, LITESPARK-012, NADINA and more, with physician reactio…
ESMO 2026: Top Melanoma Trials and KOL Voices
ESMO 2026 Madrid melanoma, October 23–26: investigational INTerpath-001 led physician discussion, followed by the NADINA 3-year update, STARBOARD and TIL data, …
ESMO 2026: Top GI Cancer Trials and KOL Voices
ESMO 2026 Madrid GI cancers, October 23–26: HARMONi-GI1, CLARITY-Gastric01, HERIZON-GEA-01, SANO, G-HOPE-001, IROCAS and AZUR-1, with verbatim physician reactio…
ESMO 2026: Top Gynecologic Cancer Trials and KOL Voices
ESMO 2026 Madrid gynecologic cancers, October 23–26: TroFuse-005 and KEYNOTE-C93 from Presidential Symposium III, plus NRG-GY020, DUO-E and BEHOLD-1, with verba…
ESMO 2026: Top Breast Cancer Trials and KOL Voices
ESMO 2026 Madrid breast cancer, October 23–26: NATALEE, KEYNOTE-B49, PANKU-Breast01, FOURLIGHT-1, SWITCH, BRIDGET, OptiTROP-Breast01 and DESTINY-Breast09, with …
ESMO 2026: Top Lung Cancer Trials and KOL Voices
ESMO 2026 Madrid lung cancer, October 23–26: DeLLphi-305, KRASCENDO-1, SAFFRON, PERSEE, OptiTROP-Lung06, PANKU-Lung01 and HERON-Lung01, with verbatim physician …
ESMO 2026: Top GU Cancer Trials and KOL Voices
ESMO 2026 Madrid GU cancers, October 23–26: VOLGA, KEYNOTE-866, DASL-HiCaP, LITESPARK-012 and TALAPRO-3, FDA approved October 26, with verbatim physician reacti…
ESMO 2026 Days 1–2: Top Trials and KOL Reactions
ESMO 2026 Days 1-2: a standing ovation for DeLLphi-305 and the crossover question physicians raised, plus INTerpath-001, VOLGA, NATALEE, PANKU-Breast01 and more…
The ESMO 2026 Debates from the KOL Social Media Threads
ESMO 2026 physician debates on X, verbatim: INTerpath-001 vs neoadjuvant IO, NATALEE's nominal OS p-value, me-too HER2 ADCs, pCR vs EFS in bladder cancer, KEYNO…
AI-Native Workflows with Your Favorite Tools: 5 Prompts to Copy
Paste a KOL Pulse trial or conference page into NotebookLM, Perplexity, Claude or ChatGPT. Five copy-ready prompts: trial timelines, trial-vs-trial tables, sent…
ENERGIZE and KEYNOTE-866: Two Negative Phase 3 MIBC Trials at ESMO 2026, and the NIAGARA Question
ESMO 2026: perioperative nivolumab (ENERGIZE, EFS HR 0.94) and pembrolizumab (KEYNOTE-866, EFS HR 0.88, OS HR 1.00) with gem/cis did not improve EFS in cisplati…
The INTerpath-001 Leak: An Embargo Break, a 25% Drop, and What Oncologists Said
ESMO lifted the LBA1 embargo after INTerpath-001 results leaked early: RFS HR 0.58 (95% CI 0.45–0.75). Moderna fell 25%. What oncologists and investors said.